This study was performed to demonstrate the transportation of an engineered MSC-produced intracellular anticancer gene product between mesenchymal stem cell (MSC) and cancer cells. MSC-mediated anticancer strategy has held great promise owing to MSCs' capacity of tumor-directed migration and the availability of specific anticancer genes. All anticancer genes that have been used in previous MSC-mediated anticancer studies were limited in functioning via extracellular mechanisms, mainly because of the restriction by cell membrane to macromolecules including proteins. In order to apply the majority of potent anticancer genes to the MSCmediated anticancer system, a specifically designed expression vector which bears an intracellular anticancer gene, PTEN, is utilized to demonstrate the feasibility of the system in cancer therapies. A transacting activator of transcription (TAT) was introduced into an expression vector followed by a segment for PTEN-RFP fusion protein. A direct demonstration of PTEN-RFP transportation between MSC and cancer cells was obtained from direct co-cultures. A marked cancer cell death was observed in indirect co-cultures with conditioned media from PTEN-transfected MSCs. The demonstration of PTEN-engineered MSC-produced PTEN transportation indicates the feasibility of applying intracellular anticancer gene expression system in MSC-mediated strategies for cancer therapy.
Introduction
Cancer remains one of the leading causes of mortality and morbidity throughout the world. To a significant extent, current conventional cancer therapies are symptomatic and passive in nature. The major obstacle to the development of effective cancer therapy is believed to be the absence of sufficient tumor specificity. Since the discovery of tumor-oriented homing capacity of mesenchymal stem cells (MSCs), the application of specific anticancer gene-engineered MSCs has held great promise for cancer therapies [1] . MSC-mediated anticancer therapy relies on tumor-specific selectivity provided by MSCs and MSC-carried anticancer agents. Homed directly at the tumor microenvironment, engineered MSCs are able to express and/or release anticancer agents to constantly act on the adjacent tumor cells. Based on the mechanisms of tumor suppression, MSC-mediated anticancer agents are classified into following categories: (1) immunostimulation, such as CX3CL1 [2] , IFN [3, 4] , IL2 [5] , IL7 [6] and IL12 [7] . (2) prodrug conversion, such as CD [8] and HSV-tk [9] . And (3) apoptosis induction, such as IL18 [10] , NK4 [11] and TRAIL [12] [13] [14] . All of these anticancer agents used in previous studies are produced by engineered MSCs and act on targeted tumor cells extracellularly. However, the majority of anticancer gene products act on tumor cells through intracellular mechanisms, such as P53, Myc and phosphatase and tensin homolog (PTEN). When MSCs are used as a vehicle to deliver intracellular anticancer genes, the anticancer gene products must be produced in MSCs and secreted into extracellular space and then penetrate into adjacent tumor cells passing through biological membrane, which is a natural barrier for most macromolecules including peptides and proteins. In this conference, we present a uniquely designed expression vector and use PTEN-engineered MSCs as an example to demonstrate cancer cell death induced by intracellular anticancer genes.
Materials and Methods

Cells and Culture Conditions
MSCs were isolated from human pancreas and ex vivo expanded as previously described [14] . Based on the minimal criteria for defining human MSCs established by the International Society of Cellular Therapy, these MSCs were verified by both membrane biomarker determination and functional differentiation. They fulfilled the characteristics of human MSCs, exhibiting positive expression of CD44 
CD105
+ and negative of CD34 -. The results of adipogenic and osteogenic differentiation also met the standards. MSCs were cultured in MEM with 10% FCS, 2 mM L-glutamine and 1% penicillin-streptomycin solution (all from Invitrogen, Carlsbad, CA, USA) and incubated at 37 o C in a humidified, 5% CO 2 atmosphere.
A human pancreatic cancer cell line (Panc-1) was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and used as target cells in the present study. Panc-1 cells were maintained as suggested by ATCC and their culture condition was kept consistent with the MSCs. In our previous study, these cells were verified negative expression for both death receptors (DR) 4 and 5, and showed no response to TNF-related apoptosis-inducing ligand (TRAIL) [15] .
Construction of PTEN-bearing Expression Vector
Mammalian expression plasmid pDsRed1-N1 was used as the backbone structure. As illustrated in Figure 1 , an 18 amino acid leading sequence and an 11 amino acid transacting activator of transcription (TAT) were inserted at the multiple cloning site followed by human PTEN (403 amino acids). A TAT-PTEN-RFP fusion protein was designated and the predicted molecular weight was around 74kd.
Plasmid Transfection of MSCs and
Determination of Cell Viability The cell viability was detected using a LIVE/DEAD Viability/Cytotoxicity Assay Kit (Invitrogen) as per the manufacturer's instruction with a slight modification. Briefly, a total of 1 x 10 5 Panc-1 cells were plated onto 24-well plates in 500 µl of MEM medium on day 0. For indirect co-cultures the media were replaced with 100% conditioned media (from both MSC PTEN and control MSCs) on day 1. The cell viability assessments were performed on day 4. The cultures were washed with PBS and then, freshly prepared working solution (250 µl per well containing 1 µM calcein AM and 2 µM EthD-1) was added directly to the cultures and incubated at room temperature for 10 min in the dark. The images were taken using a fluorescence microscope (IX71; Olympus, Markham, Ontario, Canada). 
Results
Identification of PTEN-bearing Vector
The construction of PTEN-RFP expression vector was verified by DNA sequencing, and its functional expression in MSC PTEN was confirmed by microscopic observation (Figure 2) . Immunoblotting analysis of PTEN in MSC cell lysates showed two PTEN antibody reactive bands with molecular weights 47kd and 74kd respectively, indicating the endogenous PTEN expression and additional expression induced by PTEN-RFP transfection in MSCs.
Demonstration of PTEN Travelling
PTEN is an intracellular protein and all of its tumor suppressor effects take place intracellularly. It is essential to confirm that MSC PTEN -produced PTEN is able to be secreted into the extracellular space and subsequently penetrate into adjacent cancer cells. To simulate the natural situation, cancer cells (Panc-1) were pre-labeled with carboxyfluorescein succinimidyl ester (CFSE) and seeded on culture plates one day earlier than the application of MSC PTEN (Figure 2) . 
Discussion and Conclusion
The tumor suppressor phosphatase and tensin homolog (PTEN) was discovered in 1997 [16, 17] . The PTEN gene is located at chromosome 10q23.31. Loss of heterozygosity at 10q23 occurs frequently in many advanced-stage sporadic tumors; for example, approximately 70% in glioblastomas and 60% in advanced prostate cancers [17] . PTEN is also known as mutated in multiple advanced cancer 1 (MMAC1). It functions as the central negative regulator of PI3K-AKT-mTOR pathway in controlling apoptosis. PI3K-AKT-mTOR signaling pathway is the most frequently activated pathway in human cancers, because it promotes cell growth and contributes to the evasion of apoptosis, loss of cell cycle control and genomic instability during tumorigenesis. PTEN dephosphorylates PIP 3 to PIP 2 thereby directly opposing the activity of PI3K. Compared to other classical tumor suppressor genes, PTEN is haploinsufficient because a single copy is unable to prevent cancer. Loss of its heterozygosity or partial inhibition of its expression/activity is sufficient to promote carcinogenesis [18] . Thus, restoring PTEN function in cancer cells would break down the PTEN mutation-dependent cancer cell growth, and this holds great promise for cancer therapy.
Wide-type PTEN can be introduced into cells by using viral vectors [19] or a non-viral vector-mediated delivery such as urocanic acid-modified chitosan-mediated PTEN delivery via aerosol [20] . However, engineering MSCs with PTEN could strongly potentiate the efficacy of targeted cancer therapy [21] . For the first time, a cell permeable recombinant wide-type PTEN was transfected into MSCs via fusion PTEN with transactivator of transcription (TAT). As demonstrated in Figure 3 , MSC-produced PTEN-RFP appears in the adjacent cancer cells. This observation provides a direct evidence of PTEN-RFP travelling across multiple membranes. PTEN-engineered MSCmediated cancer cell death was also confirmed in indirect cocultures with Panc-1 cells which are insensitive to TRAIL (Figure 4) . This concise demonstration reveals the application of intracellular anticancer gene-bearing expression system in MSC-mediated cancer therapy, which potentially broadens the spectrum of anticancer gene-related cancer therapy.
In conclusion, the demonstration of PTEN-engineered MSC-produced PTEN transportation indicates the feasibility of applying intracellular anticancer gene expression system in MSC-mediated anticancer treatment. PTEN-induced Panc-1 cell death also suggests possible synergistic interactions of multiple anticancer genes to highly heterogeneous carcinomas.
